<DOC>
	<DOCNO>NCT02470650</DOCNO>
	<brief_summary>The main objective study know efficiency ( costeffectiveness ) 48 week initiation antiretroviral treatment . three strategy treatment .</brief_summary>
	<brief_title>Cost-effectiveness Different Antiretroviral Treatment Patients HIV Naive</brief_title>
	<detailed_description>Secondary objective : - patient virologic response ratio 48 week ( less 50 plasma viral load ) - Change number CD4 cell 48 week - Change body composition mineral density bone ( body lumbar ) measurement DEXA ( bone mineral density scan ) 48 week - Change marker renal function ( creatinine clearance , glomerular filtration rate - eGFR - estimate rate ) renal tubular function 48 week - Rate mortality clinical progression 48 week - general tolerability safety : adverse event ( AA ) serious AA description</detailed_description>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<mesh_term>Cobicistat</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Rilpivirine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Elvitegravir , Cobicistat , Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>1negative pregnancy test woman childbearing age 2 stable HIV1 infection clinically take antiretroviral therapy 3 viral load HIV &lt; 100,000 copy 4 CD4 cell &gt; 100 cels/mm3 5 Glomerular filtration &gt; 70mlmin 6 negative HLA B5701 7.patients give informed write consent 8 opinion investigator , able follow design Protocol visit 1 . Patients virologic failure antiretroviral therapy 2 evidence prior mutation study drug 3 use antiretroviral treatment 6 month prior entry study 4 contraindication drug study 5 condition allow ensure correct compliance study 6 uncontrolled previous psychiatric illness 7 Current active addiction alcoholism</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>comparative effectiveness</keyword>
</DOC>